Lipitor vs. Leqvio

See how Lipitor and Leqvio compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Lipitor is a once-daily generic pill with decades of use, while Leqvio is an injection given twice a year after two starter doses.

  • Only Lipitor has FDA-backed evidence for directly lowering the risk of heart attack and stroke on its own.

  • Leqvio is typically added on top of a statin like Lipitor rather than used to replace it.

Lipitor vs. Leqvio Drug Summary

Lipitor

Lipitor (atorvastatin) is a statin that blocks a liver enzyme involved in making cholesterol, lowering LDL and triglycerides. It is taken as a once-daily oral tablet and is also used to cut the risk of heart attack and stroke in people with cardiovascular risk factors.

Leqvio

Leqvio (inclisiran) is a PCSK9 synthesis inhibitor given as a subcutaneous injection to lower LDL cholesterol as an add-on to diet and exercise. After two starter doses, it only needs to be injected twice a year to maintain its effect.

Lipitor vs. Leqvio Side Effects

Lipitor

Most common
Nasopharyngitis (up to 8.3%)
Arthralgia (up to 6.9%)
Diarrhea (up to 6.8%)
Pain in extremity (up to 6.0%)

Leqvio

Most common
Arthralgia (3%)
Injection site reaction (3%)
Bronchitis (3%)
Hypersensitivity (<1%)

Lipitor vs. Leqvio Dosage

Lipitor

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 10 mg once daily At the start
Maximum dose 10 mg once daily Same as starting
Dose changes None Fixed dose

Leqvio

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 284 mg single injection Day 1
Maximum dose 284 mg single injection Same as starting
Dose changes None Fixed dose

Lipitor vs. Leqvio Indications

Lipitor

Lipitor is approved to lower LDL cholesterol and triglycerides in adults and children 10 and older with dyslipidemia. It is also approved to reduce the risk of heart attack, stroke, and certain heart procedures in adults with cardiovascular risk factors, including type 2 diabetes.

  • Lowers LDL cholesterol and triglycerides in adults and kids 10+

  • Reduces heart attack, stroke, and heart surgery risk in high-risk adults

  • Reduces heart attack and stroke risk in adults with type 2 diabetes

Leqvio

Leqvio is approved as an add-on to diet and exercise to lower LDL cholesterol in adults with hypercholesterolemia. It is also approved for patients 12 and older with heterozygous or homozygous familial hypercholesterolemia.

  • Lowers LDL cholesterol as add-on therapy in adults with hypercholesterolemia

  • Lowers LDL in adults and kids 12+ with heterozygous FH

  • Lowers LDL in pediatric patients 12+ with homozygous FH

Lipitor vs. Leqvio Pros and Cons

Lipitor

Lipitor has nearly three decades of clinical use and strong evidence for lowering cardiovascular risk, backed by wide generic availability. Its main tradeoffs are the need for a daily pill and a risk of muscle-related side effects in some patients.

Pros

  • Decades of real-world data and proven reduction in heart attack and stroke risk

  • Widely available as a low-cost generic tablet taken at home

  • Approved for a broad range of patients, including children as young as 10

  • No boxed warning on the current label

Cons

  • Requires daily dosing, so missed pills can affect control

  • Carries a risk of muscle pain and, rarely, rhabdomyolysis

  • Can interact with several other medications processed by the liver

  • Not a good fit for patients who cannot tolerate statin-related muscle effects

Leqvio

Leqvio offers one of the least frequent dosing schedules among LDL-lowering injectables, needing only two shots a year after the starter doses. It is newer than Lipitor, with less long-term outcomes data, and requires clinic visits for administration.

Pros

  • Only needs two starter doses, then one injection every six months

  • Can help patients who cannot tolerate statin-related muscle side effects

  • Uses a distinct siRNA mechanism that can add LDL lowering on top of a statin

  • No boxed warning on the current label

Cons

  • Must be given by a healthcare provider, not taken at home like a pill

  • Newer drug with less long-term cardiovascular outcomes data than Lipitor

  • Carries a risk of hypersensitivity reactions including anaphylaxis and angioedema

  • Not approved as a standalone treatment for reducing cardiovascular events

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.